Larry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics Inc

Published on 16 Feb 2024 on GuruFocus.com via Yahoo Finance

Larry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics Inc

On December 31, 2023, Glenview Capital Management, led by Larry Robbins (Trades, Portfolio), made a significant addition to its investment portfolio by acquiring 1,500,000 shares of Myriad Genetics Inc (NASDAQ:MYGN). This transaction, executed at a trade price of $19.14 per share, increased the firm's total holdings in MYGN to 5,283,982 shares. The trade had a 0.65% impact on the portfolio, bringing the position to 2.29% of the portfolio and 5.97% of the company's shares.

Insight into Larry Robbins (Trades, Portfolio) and Glenview Capital Management

Warning! GuruFocus has detected 7 Warning Signs with MYGN.

Read the rest of the article

NASDAQ.MYGN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Myriad Genetics (MYGN) Announces Favorable Research Results

Myriad Genetics, Inc. MYGN recently announced results from a multi-year, real-world study that in...

Zacks via Yahoo Finance 11 Apr 2024

Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay

Myriad Genetics, Inc. MYGN recently announced the issuance of a patent by the United States Paten...

Zacks via Yahoo Finance 27 Mar 2024

Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact

Myriad Genetics, Inc. MYGN recently entered into a research partnership with National Cancer Cent...

Zacks via Yahoo Finance 2 Mar 2024

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call Transcript February 27, 2024 Myriad Gen...

Insider Monkey via Yahoo Finance 29 Feb 2024

Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down

Myriad Genetics, Inc. MYGN reported an adjusted earnings per share (EPS) of 4 cents per share in ...

Zacks via Yahoo Finance 28 Feb 2024

Myriad Genetics Inc (MYGN) Reports 11% Revenue Growth in Q4 and Full-Year 2023

Revenue Growth: Myriad Genetics Inc (NASDAQ:MYGN) reported an 11% year-over-year increase in both...

GuruFocus.com via Yahoo Finance 28 Feb 2024

Debt-Addicted Companies Look to Equity as Interest Costs Skyrocket

(Bloomberg) -- For the better part of a decade, Bryan Riggsbee did what countless other finance c...

Bloomberg via Yahoo Finance 27 Feb 2024

Larry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics Inc

On December 31, 2023, Glenview Capital Management, led by Larry Robbins (Trades, Portfolio), made...

GuruFocus.com via Yahoo Finance 16 Feb 2024

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 221% Above Its Share Price

Key Insights Myriad Genetics' estimated fair value is US$57.52 based on 2 Stage Free Cash Flow to...

Simply Wall St. via Yahoo Finance 5 Jan 2024

Myriad Genetics' (MYGN) New Platform to Advance Cancer Care

Myriad Genetics, Inc. MYGN recently launched the Myriad Collaborative Research Registry (“MCRR”) ...

Zacks via Yahoo Finance 22 Dec 2023

News

Larry Robbins' Glenview Capital Management Bolsters Stake in Myriad Genetics Inc

NASDAQ.MYGN price evolution

Want to become a better investor?